Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas

Virchows Archiv

Volumn 453, Issue 6, 2008, Pages 627-635

  Dacic, Sanja ^a   Kothmaier, Hannelore ^b   Land, Stephanie ^c   Shuai, Yongli ^c   Halbwedl, Iris ^b   Morbini, Patrizia ^d   Murer, Bruno ^e   Comin, Camilla ^f   Galateau Salle, Françoise ^g   Demirag, Funda ^h   Zeren, Handan ⁱ   Attanoos, Richard ^j   Gibbs, Alan ^j   Cagle, Philip ^k   Popper, Helmut ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Instituto di Anatomia Pathologica   (Italy)

^e Ospedale Umberto I   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g CHU CÔTE DE NACRE   (France)

^h Ataturk Chest Disease and Thoracic Surgery Hospital   (Turkey)

ⁱ Adana University   (Turkey)

^j CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^k HOUSTON METHODIST HOSPITAL   (United States)

more..

Author keywords

FISH; Immunohistochemistry; p16; Pleural mesothelioma; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 55849100717     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-008-0689-3     Document Type: Article

References (30)

1. S Neragi-Miandoab 2006 Multimodality approach in management of malignant pleural mesothelioma Eur J Cardio Thorac Surg 29 14 19
2. BWS Robinson AW Musk RA Lake 2005 Malignant mesothelioma Lancet 366 397 408
3. L Bonomo B Feragalli R Sacco 2000 Malignant pleural disease Eur J Radiol 34 98 118
4. M Carbone P Rizzo PM Grimley 1997 Simian virus-40 large-T antigen binds p53 in human mesotheliomas Nat Med 3 908 912
5. AF Gazdar M Carbone 2003 Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40 Clin Lung Cancer 5 177 181
6. A Tsiouris RK Walesby 2007 Malignant pleural mesothelioma: current concepts in treatment Nat Clin Pract Oncol 4 344 352
7. VW Rusch 1996 A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group Lung Cancer 14 1 12
8. DJ Sugarbaker RM Flores MT Jaklitsch 1999 Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 54 63
9. D Curran T Sahmoud P Therasse 1998 Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 145 152
10. JE Herndon MR Green AP Chahinian 1998 Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 723 731
11. R Bueno J Reblando J Glickman 2004 Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma Ann Thorac Surg 78 1774 1776
12. JPC Steele 2002 Prognostic factors in mesothelioma Semin Oncol 29 36 40
13. W Weder P Kestenholz C Taverna 2004 Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.[see comment] J Clin Oncol 22 3451 3457
14. T Hirao R Bueno C-J Chen 2002 Alterations of the p16(INK4) locus in human malignant mesothelial tumors Carcinogenesis 23 1127 1130
15. P Kumar RA Kratzke 2005 Molecular prognostic markers in malignant mesothelioma Lung Cancer 49 Suppl 1 S53 S60
16. AY Lee DJ Raz B He 2007 Update on the molecular biology of malignant mesothelioma Cancer 109 1454 1461
17. E Pisick R Salgia 2005 Molecular biology of malignant mesothelioma: a review Hematol Oncol Clin North Am 19 997 1023
18. PB Illei VW Rusch MF Zakowski 2003 Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas Clin Cancer Res 9 2108 2113
19. F Lopez-Rios S Chuai R Flores 2006 Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction Cancer Res 66 2970 2979
20. M Musti E Kettunen S Dragonieri 2006 Cytogenetic and molecular genetic changes in malignant mesothelioma Cancer Genet Cytogenet 170 9 15
21. S Singhal R Wiewrodt LD Malden 2003 Gene expression profiling of malignant mesothelioma Clin Cancer Res 9 3080 3097
22. JB Prins KA Williamson MM Kamp 1998 The gene for the cyclin-dependent- kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma Int J Cancer 75 649 653
23. S Xio D Li J Vijg 1995 Codeletion of p15 and p16 in primary malignant mesothelioma Oncogene 11 511 515
24. S Chiosea A Krasinskas PT Cagle 2008 Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas Mod Pathol 21 742 747
25. PB Illei M Ladanyi VW Rusch 2003 The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions Cancer 99 51 56
26. Churg R, Roggli V, Galateau-Salle F (2004) Tumours of the pleura. In: Travis W, Brambilla E, Muller-Hermelink H, Harris C (eds) World Health Organization classification of tumours, pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC, Lyon, pp 126-136
27. H Kothmaier F Quehenberger I Halbwedl 2008 EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors Thorax 63 345 351
28. AC Borczuk RN Taub M Hesdorffer 2005 P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma Clin Cancer Res 11 3303 3308
29. A Batova MB Diccianni M Omura-Minamisawa 1999 Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro Cancer Res 59 1492 1497
30. H Harasawa Y Yamada M Kudoh 2002 Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL) Leukemia 16 1799 1807